Cambridge, Mass. — Enveric Biosciences announced it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent covering a novel class of aminated tryptamine derivatives—compounds designed to deliver the therapeutic benefits of psychedelics without inducing hallucinations.
The patent covers both the molecular compositions and their therapeutic use, bolstering Enveric’s intellectual property portfolio in the emerging field of non-hallucinogenic psychedelic-inspired treatments for psychiatric and neurological conditions such as depression, PTSD, anxiety, and cognitive impairments.
Developed using Enveric’s proprietary drug discovery platform, the new compounds—described as neuroplastogens—have demonstrated minimal hallucinogenic effects in preclinical studies. Key indicators such as the Head Twitch Response (HTR) and 5-HT2A receptor activation in rodent models showed significantly reduced hallucinogenic potential, according to the company.
“The allowance of this patent adds another important layer of innovation to our portfolio,” said Dr. Joseph Tucker, CEO of Enveric Biosciences. “Unlike traditional psychedelics that often require supervised administration due to hallucinatory side effects, our compounds are designed for safe, flexible outpatient use—making them more compatible with current healthcare delivery systems.”
Enveric’s strategy focuses on developing next-generation neuroplastogens—compounds that promote neural plasticity without causing hallucinations—to overcome the logistical and safety barriers that limit the widespread use of psychedelic-based therapies.
“This milestone highlights our commitment to creating safe, scalable, and effective treatments for mental health,” added Dr. Tucker. “It also reflects the value of our integrated discovery platform, which blends computational chemistry with advanced medicinal design to accelerate the path to clinical development.”
With the new patent, Enveric aims to solidify its leadership in the space and position itself as a key innovator in the future of mental health therapeutics.
